The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Phase I study of motixafortide +/- natalizumab to mobilize HSCs for gene therapy in SCD
Zachary Crees, MD, Washington University School of Medicine, St. Louis, MO, discusses a Phase I study (NCT05618301) demonstrating that the use of motixafortide, a CXCR4 inhibitor, both alone and in combination with natalizumab, a VLA-4 inhibitor, significantly improved the mobilization of hematopoietic stem cells (HSCs) for gene therapy in sickle cell disease (SCD), without increasing the risk of toxicities. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
